Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AMLCAMBRIDGE, ...

Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK) therapy, experienced complete remission after not responding to ...

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ziftomenib for adult patients with relapsed or refractory acute myeloid leukemia with a ...

A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...

What Is Revuforj, and Why Does It Matter? Revuforj (revumenib) is an oral medicine approved for treating a type of cancer called acute myeloid leukemia (AML) that affects your bone marrow and blood.

Annamycin plus cytarabine achieved a 40% preliminary remission rate in relapsed AML, including patients who previously received Venclexta-based therapy. Early findings from the ongoing MIRACLE ...

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Ther ...